The Impact of COVID-19 on the Epidemiology of Carbapenem Resistance
Antibiotics · 11.09.2025 · 14 (9) · 916
DOI: 10.3390/antibiotics14090916 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 11.09.2025. Verfasst von Aikaterini Sakagianni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, Sismanogleio General Hospital, 15126 Marousi, Greece. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The global COVID-19 pandemic has significantly disrupted healthcare systems, inadvertently influencing the epidemiology of antimicrobial resistance (AMR). Among the most critical AMR threats are carbapenem-resistant organisms (CROs), which include carbapenem-resistant Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa. This review explores the pandemic’s impact on carbapenem resistance patterns worldwide.
Objectives
This study aimed to assess the effects of the COVID-19 pandemic on carbapenem resistance trends, identify key drivers, and discuss implications for clinical practice and public health policy.
Methods
A comprehensive review of peer-reviewed literature, national surveillance reports, and WHO/ECDC data from 2019 to 2025 was conducted, with emphasis on hospital-acquired infections, antimicrobial use, and infection control practices during the pandemic.
Results
The pandemic has led to increased use of broad-spectrum antibiotics, including carbapenems, often in the absence of confirmed bacterial co-infections. Overwhelmed healthcare systems and disruptions in infection prevention and control (IPC) measures have facilitated the spread of carbapenem-resistant organisms, particularly in intensive care settings. Surveillance data from multiple countries show a measurable increase in CRO prevalence during the pandemic period, with regional variations depending on healthcare capacity and stewardship infrastructure.
Conclusions
COVID-19 has accelerated the emergence and dissemination of carbapenem resistance, underscoring the need for resilient antimicrobial stewardship and IPC programs even during public health emergencies. Integrating pandemic preparedness with AMR mitigation strategies is critical for preventing further escalation of resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Intensive Care Unit, Sismanogleio General Hospital, 15126 Marousi, Greece.
- Anesthesiology Department, General Hospital of Athens "G. Gennimatas", 11527 Athens, Greece.
- Internal Medicine Department, Sismanogleio General Hospital, 15126 Marousi, Greece.
- School of Science and Technology, Hellenic Open University, 26131 Patras, Greece.
- Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Aikaterini Sakagianni, Georgios Feretzakis
Zitieren
APA
Sakagianni, A., Koufopoulou, C., Koufopoulos, P., Feretzakis, G., & Koumaki, V. (2025). The Impact of COVID-19 on the Epidemiology of Carbapenem Resistance. Antibiotics, 14(9), 916. https://doi.org/10.3390/antibiotics14090916
Vancouver
Sakagianni A, Koufopoulou C, Koufopoulos P, Feretzakis G, Koumaki V. The Impact of COVID-19 on the Epidemiology of Carbapenem Resistance. Antibiotics. 2025;14(9):916. doi:10.3390/antibiotics14090916
BibTeX
@article{Sakagianni2025,
author = {Sakagianni, Aikaterini and Koufopoulou, Christina and Koufopoulos, Petros and Feretzakis, Georgios and Koumaki, Vasiliki},
title = {The Impact of COVID-19 on the Epidemiology of Carbapenem Resistance},
journal = {Antibiotics},
year = {2025},
volume = {14},
number = {9},
pages = {916},
doi = {10.3390/antibiotics14090916}
}
EUVIMED